Biogen Idec Inc. announced today that its presentation at the Deutsche Bank 37th Annual Healthcare Conference will be webcast live on Tuesday, May 8, 2012 at 10:00 a.m. ET.

Anacor Pharmaceuticals announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at the Deutsche Bank Annual Health Care Conference on Monday May 7, 2012 at 4:10 p.m. ET in Boston, Massachusetts.

ClinStar, LLC, an established clinical research organization providing clinical development services in the emerging markets of Russia and Eastern Europe to the biopharmaceutical industry, announced today that President and CEO David Passov will present at Outsourcing in Clinical Trials Europe conference May 8-9 at Mövenpick Hotel Zürich-Regensdorf in Zürich, Switzerland.

Novasep, a leading supplier of purification and production solutions for the life sciences industry, announces two new managerial appointments. Jean-Claude Romain becomes the group's corporate quality director and a member of Novasep's executive committee, while Alain Lamproye joins Novasep Process, the company's biomolecules division, as director of Novasep Belgium and becomes a member of Novasep Process' management committee.

Adocia, a biotechnology company specialized in the development of best-in-class medicines with already approved therapeutic proteins, announces today positive results from its Phase II clinical trial evaluating the safety and efficacy of BioChaperone(R) combined with PDGF-BB for the treatment of diabetic foot ulcer. This product has been compared with Regranex(R), a commercially available hydrogel of PDGF-BB.

Novasep, a leading provider of purification-based manufacturing solutions for lifescience molecules, announces today that Cerenis Therapeutics has been invited by BioProcess International to present its major project CER – 001 ApoA1 - HDL mimetic drug candidate, and describe how Novasep played a critical role in the project by successfully achieving the transfer and scale up of Apo-A1 production.

India is the world's fourth largest pharmaceutical market in terms of volume and ranks fifteen in terms of value (US$8 billion). In the recent past, pharma companies have seen the growth rate of their rural market sales double with the help of aggressive marketing strategies. India's rural drug market alone grew by 18.8% during 2010-2011 as compared to a 10.9% growth in the previous year.

According to PricewaterhouseCoopers, the Indian pharmaceutical market is expected to grow from US$11 billion to US$74 billion by 2020. All India Organisation of Chemists and Druggists (AIOCD) reported that India's pharmaceutical market grew at 15.7% during December 2011, with growth in key therapy areas, including anti-diabetics, derma and vitamins. How can you ensure that your firm is rightly positioned to become the next superpower for pharma manufacturing needs?

Immutep and Lonza announced today an agreement for cell line selection, master cell banking and process development of ImmuFact(R) IMP321.

Novasep, a leading supplier of manufacturing solutions to the life sciences industries, today announces the opening of a new 2,000 m2 facility in Shanghai Pudong district, China. The site will boost Novasep's process development and engineering capabilities to cater for ever-increasing Chinese and East Asian demand. These facilities will also add to Novasep’s existing 12 global synthesis and process sites in France, US, Germany, Belgium and The Bahamas.